{"_buckets": {"deposit": "8aaa660f-118c-4bb4-a8c0-60d32162e162"}, "_deposit": {"id": "30080", "owners": [], "pid": {"revision_id": 0, "type": "depid", "value": "30080"}, "status": "published"}, "_oai": {"id": "oai:nagoya.repo.nii.ac.jp:00030080"}, "item_9_biblio_info_6": {"attribute_name": "\u66f8\u8a8c\u60c5\u5831", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2020-05", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "2", "bibliographicPageEnd": "160", "bibliographicPageStart": "151", "bibliographicVolumeNumber": "82", "bibliographic_titles": [{"bibliographic_title": "Nagoya Journal of Medical Science"}]}]}, "item_9_description_4": {"attribute_name": "\u6284\u9332", "attribute_value_mlt": [{"subitem_description": "Among elderly patients with acute myeloid leukemia (AML), especially those who are unfit for intensive chemotherapy, a policy of reduced-intensity chemotherapy or conservative observation has been chosen, resulting in unmet medical needs. Clinical trials using anticancer drugs including antimetabolites or drugs targeted to cell cycle-related molecules failed to show superiority over conventional treatments. Recently, drugs targeted to Bcl-2, SMO, FLT3, and IDH1/2 have been shown to prolong overall survival alone or in combination with reduced-intensity chemotherapy. These treatments are likely to reshape the therapeutic landscape of AML, which will be personalized for individual patients based on leukemia genetics.", "subitem_description_type": "Abstract"}]}, "item_9_identifier_registration": {"attribute_name": "ID\u767b\u9332", "attribute_value_mlt": [{"subitem_identifier_reg_text": "10.18999/nagjms.82.2.151", "subitem_identifier_reg_type": "JaLC"}]}, "item_9_publisher_32": {"attribute_name": "\u51fa\u7248\u8005", "attribute_value_mlt": [{"subitem_publisher": "Nagoya University Graduate School of Medicine, School of Medicine"}]}, "item_9_relation_43": {"attribute_name": "\u7570\u7248\u3067\u3042\u308b", "attribute_value_mlt": [{"subitem_relation_type": "isVersionOf", "subitem_relation_type_id": {"subitem_relation_type_id_text": "http://www.med.nagoya-u.ac.jp/medlib/nagoya_j_med_sci/822.html ", "subitem_relation_type_select": "URI"}}]}, "item_9_select_15": {"attribute_name": "\u8457\u8005\u7248\u30d5\u30e9\u30b0", "attribute_value_mlt": [{"subitem_select_item": "publisher"}]}, "item_9_source_id_61": {"attribute_name": "ISSN\uff08Online\uff09", "attribute_value_mlt": [{"subitem_source_identifier": "2186-3326", "subitem_source_identifier_type": "ISSN"}]}, "item_9_source_id_7": {"attribute_name": "ISSN\uff08print\uff09", "attribute_value_mlt": [{"subitem_source_identifier": "0027-7622", "subitem_source_identifier_type": "ISSN"}]}, "item_creator": {"attribute_name": "\u8457\u8005", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Naoe, Tomoki"}], "nameIdentifiers": [{"nameIdentifier": "99231", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "\u30d5\u30a1\u30a4\u30eb\u60c5\u5831", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2020-06-01"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "01_Naoe.pdf", "filesize": [{"value": "750.6 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 750600.0, "url": {"label": "01_Naoe.pdf", "url": "https://nagoya.repo.nii.ac.jp/record/30080/files/01_Naoe.pdf"}, "version_id": "fd694a1b-ab66-453b-82e7-7b19b46ef039"}]}, "item_keyword": {"attribute_name": "\u30ad\u30fc\u30ef\u30fc\u30c9", "attribute_value_mlt": [{"subitem_subject": "elderly patients", "subitem_subject_scheme": "Other"}, {"subitem_subject": "acute myeloid leukemia", "subitem_subject_scheme": "Other"}, {"subitem_subject": "chemotherapy", "subitem_subject_scheme": "Other"}, {"subitem_subject": "molecule-targeted drug", "subitem_subject_scheme": "Other"}, {"subitem_subject": "prognosis", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "\u8a00\u8a9e", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "\u8cc7\u6e90\u30bf\u30a4\u30d7", "attribute_value_mlt": [{"resourcetype": "departmental bulletin paper", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "How to improve outcomes of elderly patients with acute myeloid leukemia: era of excitement", "item_titles": {"attribute_name": "\u30bf\u30a4\u30c8\u30eb", "attribute_value_mlt": [{"subitem_title": "How to improve outcomes of elderly patients with acute myeloid leukemia: era of excitement"}]}, "item_type_id": "9", "owner": "1", "path": ["499/508/509/2504"], "permalink_uri": "https://doi.org/10.18999/nagjms.82.2.151", "pubdate": {"attribute_name": "\u516c\u958b\u65e5", "attribute_name_i18n": "\u516c\u958b\u65e5", "attribute_value": "2020-06-01"}, "publish_date": "2020-06-01", "publish_status": "0", "recid": "30080", "relation": {}, "relation_version_is_last": true, "title": ["How to improve outcomes of elderly patients with acute myeloid leukemia: era of excitement"], "weko_shared_id": null}